Literature DB >> 17357504

Reversal of adriamycin resistance in human mammary cancer cells by small interfering RNA of MDR1 and MDR3 genes.

Lan Xiao1, Rui Gao, Shi Lu, Lirong Ren, Zehua Wang.   

Abstract

The purpose of this paper is to investigate the reversal effect of small interfering RNA (siRNA) targeting MDR1 and MDR3 genes on the resistance of MCF-7/ADR cells to adriamycin. siRNA plasmid vector targeting MDR1 and MDR3 genes was transfected into MCF-7/ADR cells, and then was stained with Annexin-V FITC (fluorescein isothiocyanate conjugated) to detect the early stage cell apoptosis by flow cytometry (FCM). 50% inhibition concentration (IC50) of adriamycin for MCF-7/ADR cells was determined by MTT method. MDR1 and MDR3 mRNA was assessed by RT-PCR. Treatment of MCF-7/ADR cells with the two kinds of siRNAs resulted in a reversal of adriamycin resistance of MDR to different extents. 1) The apoptosis efficiency of MDR1 and MDR3 siRNA vector after transfection was (18.21+/-1.65) % and (9.07+/-2.16) % respectively (P<0.05), and there was significant differences in the apoptosis efficiency between p Suppressor Neo vector and the MDR1 siRNA or MDR3 siRNA vector (P<0.01); 2) The reversal effect of MDR1 siRNA is higher than that of MDR3 siRNA (P<0.05); 3) The expression of MDRI and MDR3 mRNA can be restrained by p Suppressor Neo MDR1 and MDR3 siRNA respectively, and the reduction in the mRNA level was in a time-dependent manner (P<0.01). MDR1 and MDR3 gene silencing can enhance intracellular adriamycin accumulation in MCF-7/ADR cells, improve sensitivity of MCF-7/ADR cells to adriamycin, and induce cell apoptosis. The reversal effect of adriamycin resistance by siRNA of MDR1 was more effective than that of MDR3.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17357504     DOI: 10.1007/s11596-006-0630-4

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  9 in total

1.  The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice.

Authors:  D R Johnson; R A Finch; Z P Lin; C J Zeiss; A C Sartorelli
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

2.  Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo.

Authors:  Luc Barraud; Philippe Merle; Emilienne Soma; Lydie Lefrançois; Sylviane Guerret; Michèle Chevallier; Catherine Dubernet; Patrick Couvreur; Christian Trépo; Ludmila Vitvitski
Journal:  J Hepatol       Date:  2005-05       Impact factor: 25.083

3.  MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping.

Authors:  A J Smith; A van Helvoort; G van Meer; K Szabo; E Welker; G Szakacs; A Varadi; B Sarkadi; P Borst
Journal:  J Biol Chem       Date:  2000-08-04       Impact factor: 5.157

Review 4.  Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.

Authors:  Hilary Thomas; Helen M Coley
Journal:  Cancer Control       Date:  2003 Mar-Apr       Impact factor: 3.302

5.  Cytometric study of intracellular P-gp expression and reversal of drug resistance.

Authors:  G Labroille; F Belloc; C Bilhou-Nabera; S Bonnefille; E Bascans; M R Boisseau; P Bernard; F Lacombe
Journal:  Cytometry       Date:  1998-06-01

6.  Inducible, reversible, and stable RNA interference in mammalian cells.

Authors:  Sunita Gupta; Rebecca A Schoer; James E Egan; Gregory J Hannon; Vivek Mittal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-04       Impact factor: 11.205

Review 7.  New approaches in identifying drugs to inactivate oncogene products.

Authors:  Ruiwu Liu; Ching-Yi Hsieh; Kit S Lam
Journal:  Semin Cancer Biol       Date:  2004-02       Impact factor: 15.707

8.  Selective inhibition of P-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator.

Authors:  Dong Xu; Dongjiu Ye; Michael Fisher; R L Juliano
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

9.  Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1.

Authors:  E Yagüe; C F Higgins; S Raguz
Journal:  Gene Ther       Date:  2004-07       Impact factor: 5.250

  9 in total
  1 in total

1.  Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells.

Authors:  Yan Yang; Zehua Wang; Minfang Li; Shi Lu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.